Winner Medical(SZ:300888)2024-04-24 14:31Financial Performance - The company's operating revenue for Q1 2024 was ¥1,909,017,281.07, a decrease of 18.84% compared to ¥2,352,114,690.56 in the same period last year[4]. - Net profit attributable to shareholders decreased by 51.60% to ¥182,424,811.95 from ¥376,938,135.34 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥144,201,815.60, down 53.46% from ¥309,834,876.09 in the previous year[4]. - Basic and diluted earnings per share both decreased by 51.56% to ¥0.31 from ¥0.64 year-on-year[4]. - In Q1 2024, the company reported a total revenue of 1.91 billion yuan, a year-on-year decrease of 18.8%[21]. - Net profit attributable to shareholders was 180 million yuan, down 51.6% year-on-year[21]. - Net profit for Q1 2024 was CNY 193,513,122.53, representing a decline of 50.1% from CNY 387,940,532.93 in Q1 2023[33]. - The company reported a total comprehensive income of CNY 194,542,000.87, down from CNY 387,215,004.85 in Q1 2023[34]. Cash Flow and Investments - The company's cash flow from operating activities improved by 26.78%, with a net cash outflow of ¥163,462,761.04 compared to ¥223,247,317.38 in the same period last year[4]. - The net cash flow from investment activities was -309,795,884.33, compared to -178,675,407.47 in the previous year, indicating a decline in investment performance[38]. - Cash inflow from financing activities totaled 453,003,451.87, down from 683,000,000.00 year-over-year[38]. - The net cash flow from financing activities was -484,059,598.07, contrasting with a positive net flow of 262,960,743.92 in the same quarter last year[38]. - The company reported a total cash outflow from investment activities of 1,124,307,276.17, compared to 1,624,404,139.25 in the prior year[38]. - The cash outflow for repayment of debts was 733,000,000.00, significantly higher than 363,000,000.00 in the previous year[38]. - The company’s cash and cash equivalents decreased by 954,811,754.85 during the quarter, compared to a decrease of 142,627,979.28 in the same quarter last year[38]. - The company's cash and cash equivalents at the end of the period were approximately 3.75 billion yuan, down from 4.71 billion yuan at the beginning of the period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥16,494,937,257.25, a decrease of 3.61% from ¥17,112,022,449.97 at the end of the previous year[4]. - Total liabilities decreased to approximately 4.33 billion yuan from 5.00 billion yuan[29]. - The total liabilities and equity amounted to CNY 16,494,937,257.25, a decrease from CNY 17,112,022,449.97 year-over-year[30]. - The total equity attributable to shareholders of the parent company increased slightly to CNY 11,572,720,973.48 from CNY 11,533,224,328.00[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,872[17]. - The largest shareholder, Steady Group Limited, holds 69.12% of the shares, totaling 406,614,387 shares[17]. - The company has a total of 4,354,560 shares held in the repurchase special account as of March 31, 2024[18]. - The number of shares with limited sales at the end of the period is 406,766,052, with 10,500 shares released from restrictions during the period[20]. - The company has no preferred shareholders or major changes in the top 10 shareholders participating in margin trading[19]. - The top 10 shareholders hold a combined total of 99.99% of the shares, with no significant changes in their holdings[19]. - The company has not issued any new shares or products during this reporting period[20]. - The company plans to maintain its current shareholder structure without any immediate changes in strategy or market expansion[20]. Research and Development - R&D expenses decreased by 31.64% to ¥75,999,859.76 from ¥111,178,989.49 in the previous year, primarily due to a reduction in R&D projects[13]. - Research and development expenses decreased to CNY 75,999,859.76, down 31.7% from CNY 111,178,989.49 in the previous year[33]. Taxation - The company received tax refunds of ¥25,352,683.07, an increase of 130.29% compared to ¥11,008,837.69 in the same period last year[15]. - Cash paid for various taxes decreased by 65.54% to ¥100,041,606.75 from ¥290,271,355.72, reflecting a decline in medical performance[15]. Product Performance - Medical consumables revenue was 860 million yuan, a decline of 37.3% year-on-year, while infection protection products saw a significant drop of 87.6% to 80 million yuan[23]. - Regular medical consumables revenue grew by 4.3% to 780 million yuan, with high-end wound dressing products increasing by 33.9% to 180 million yuan[23]. - International sales channels for medical consumables achieved 380 million yuan, up 21.3% year-on-year, accounting for 44.6% of the medical consumables revenue[23]. - Health consumer products revenue reached 1.04 billion yuan, a growth of 7.1% year-on-year, with non-woven consumer products growing by 10.0% to 550 million yuan[23]. - The core product, wet and dry cotton towels, generated 270 million yuan in revenue, reflecting a 20.0% increase[23]. Other Information - The company has not reported any mergers or acquisitions in this quarter[20]. - There are no new technological developments or product launches mentioned in the report[20]. - The company has not yet adopted the new accounting standards for the current year[39]. - The first quarter report was not audited[40]. - The board of directors issued the report on April 25, 2024[41].